These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 12883185

  • 1. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):318-23. PubMed ID: 12883185
    [Abstract] [Full Text] [Related]

  • 2. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
    Chueh SC, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):375-82. PubMed ID: 12883196
    [Abstract] [Full Text] [Related]

  • 3. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Jul 27; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 4. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 27; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 5. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 6. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
    Boratynska M, Banasik M, Patrzalek D, Klinger M.
    Exp Clin Transplant; 2008 Mar 27; 6(1):59-66. PubMed ID: 18405247
    [Abstract] [Full Text] [Related]

  • 7. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Mar 27; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 8. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 9. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients.
    Langer RM, Kahan BD.
    Transplantation; 2002 Sep 27; 74(6):804-8. PubMed ID: 12364859
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 11. Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
    Derweesh IH, Ismail HR, Goldfarb DA, Araki M, Zhou L, Modlin C, Krishnamurthi V, Flechner SM, Novick AC.
    BJU Int; 2008 Jun 27; 101(11):1415-9. PubMed ID: 18190623
    [Abstract] [Full Text] [Related]

  • 12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 15. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.
    Liver Transpl; 2003 Oct 15; 9(10):1079-85. PubMed ID: 14526403
    [Abstract] [Full Text] [Related]

  • 16. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G.
    Liver Transpl; 2001 May 15; 7(5):401-8. PubMed ID: 11349259
    [Abstract] [Full Text] [Related]

  • 17. [Lymphocele and kidney transplantation].
    Langer R, Tóth A, Máthé Z, Remport A, Járay J, Kahan BD.
    Orv Hetil; 2007 Aug 05; 148(31):1475-80. PubMed ID: 17656338
    [Abstract] [Full Text] [Related]

  • 18. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 19. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
    Yakupoglu YK, Buell JF, Woodle S, Kahan BD.
    Transplant Proc; 2006 Mar 27; 38(2):358-61. PubMed ID: 16549120
    [Abstract] [Full Text] [Related]

  • 20. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL.
    Clin Transplant; 1994 Aug 27; 8(4):388-95. PubMed ID: 7949545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.